SIGA Technologies, Inc. is a commercial-stage pharmaceutical enterprise focused primarily on the health security market, specializing in the development and deployment of countermeasure solutions against biothreats. Its flagship product is TPOXX (tecovirimat), an antiviral medication approved for the treatment of smallpox, which is stockpiled by national governments and public health agencies worldwide for biodefense preparedness and emerging viral outbreak responses.